Results 91 to 100 of about 12,211 (152)

Do apelin and ghrelin play a role in multiple sclerosis? The analysis of patients treated with immunomodulatory therapies. [PDF]

Front Immunol
Adamczyk B, Morawiec N, Rakoca M, Sowa A, Sawa K, Adamczyk-Sowa M.   +5 more
europepmc   +1 more source

The wearing-off effect with natalizumab: Back to the drawing board. [PDF]

Neurotherapeutics
Afzal S, Conway DS.
europepmc   +1 more source

Biological and clinical stability after switching from intravenous to subcutaneous natalizumab in RRMS under standard and extended dosing. [PDF]

Front Immunol
Agundez-Moreno A, Presas-Rodríguez S, González-García AM, Teniente-Serra A, Arcos-Ribas B, Martínez-Caceres EM, Querol L, Martín-Aguilar L, Vidal-Jordana Á, Meca Lallana JE, Dos-Santos C, Millan J, Valero G, Cano A, Casado V, Boltes-Alandi A, Hervas-Garcia JV, Brieva L, Alvarez G, Ramo-Tello C.   +19 more
europepmc   +1 more source

Real-world pharmacovigilance analysis of the association between multiple sclerosis disease-modifying therapies and intervertebral disc herniation. [PDF]

Front Pharmacol
Yang N, Liu H, Zhou Y, Feng H.
europepmc   +1 more source

Pediatric Radiologically Isolated Syndrome (RIS): A Case with Active Disease 18 Years Later. [PDF]

Neurol Ther
Ghezzi A, Pozzato M, Annovazzi P, Antozzi C, Erbetta A, Torri Clerici V.   +5 more
europepmc   +1 more source

Adjunctive Dulaglutide in Relapsing-Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial. [PDF]

Neurol Ther
Šiarnik P, Rádiková Ž, Kollár B, Kutšálová M, Penesová A, Havranová A, Imrich R, Vlček M, Žitňanová I, Krastev G, Turčáni P.   +10 more
europepmc   +1 more source

Trajectories of processing speed in multiple sclerosis across disease-modifying therapies. [PDF]

J Neurol
Guo J, Johansson E, Hillert J, Olsson T, Alfredsson L, Hedström AK.   +5 more
europepmc   +1 more source

International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges. [PDF]

Neurol Ther
Chan A, Alroughani R, Calabrese M, Havrdová EK, Obeidat AZ, Schmierer K, Andersson M, Bek L, Savarin C, Korich J, Bonsignore L, de Seze J.   +11 more
europepmc   +1 more source

Late-Onset Neutropenia After Rituximab in Multiple Sclerosis: Incidence, Predictors, and Outcomes in a Retrospective Multicenter Cohort. [PDF]

Neurol Neuroimmunol Neuroinflamm
Hallberg S, Kallin S, Evertsson B, Boremalm M, de Flon P, Salzer J, Lycke J, Fink K, Svenningsson A.   +8 more
europepmc   +1 more source

JAK/STAT signaling pathway inhibitors in neurodegenerative diseases: current status and future perspectives. [PDF]

Front Aging Neurosci
Yang HX, Su BW, Bao YN, Wang WH, Lao JY, Ji HY, Han S, Cui XH, Ren HW, Luan ZL.   +9 more
europepmc   +1 more source